ClearNote Health Secures $52 Million in Series D Financing and Strengthens Leadership Team to Accelerate Growth in Early Cancer Detection
Proceeds will support continued commercial expansion, operational scale-up, clinical study execution, and product development
Clinical oncology diagnostics veteran Kevin Keegan appointed president and chief operating officer
ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced the close of $52 million in Series D financing, along with the appointment of industry veteran Kevin Keegan as president and chief operating officer. The financing and leadership expansion position ClearNote Health to accelerate growth amid increasing demand for more accurate, accessible, and affordable noninvasive tools for early cancer detection.
With this Series D financing, the company has received total funding of more than $185 million from leading institutional investors. The round was led by founding investor Mattias Westman and a global, large, long-only active manager. Other participants included former CEO and chairman of Citigroup Sandy Weill, ClearNote Health co-founder Dr. Stephen Quake of Stanford University, a large Seattle-based family office, and other U.S. and international-based institutional investors. Proceeds from the financing will support continued commercial expansion, clinical study execution, product development, and broader global access to ClearNote Health’s portfolio of Avantect® early cancer detection tests and Virtuoso™ epigenomic drug development platform.
